Save Up To 70% with generic medications and up to 40% with brand name drugs. Get FREE WorldWide shipping on $149 or more...
Multiple Sclerosis » Merck Seeks European License For...
Home » News » Merck Seeks European License For...
Merck Seeks European License For Cladribine for relapsing remitting MS
Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington.
Read full article @ MedicalNewsToday
Read Also Other "Multiple Sclerosis" News
-
Jefferson Award Honors Doctor Determined To Cure Rare Disease HIBM
A Los Angeles doctor who has made it his life's work to find a cure for the...
-
New Research Suggests Smoking May Worsen MS
Research published in the journal Neurology suggests that smoking may...
